Phase 4 trial of Tofersen closes recruitment
Trial at a glance
- Status
- Active, not recruiting
- Phase
- Phase 4
- Intervention
- Tofersen (drug) also known as BIIB067, QALSODY
- Enrolment
- 12 participants (estimated)
- Site
- China
- Sponsor
- Biogen
- Registration
- NCT07223723
Compass reports what the trial registry states. A trial being registered, recruiting or completed is not evidence that a treatment works.
This Phase 4 interventional study is evaluating tofersen in Chinese participants with SOD1 amyotrophic lateral sclerosis. The registry now says recruitment is closed and the study is active but not recruiting, with 12 participants estimated and sites in China.
Why this matters
The opportunity to join this study has passed because recruitment is closed. The registry lists a planned completion date of May 2027, and no results have been posted.
Trial updates
Recruitment closed — 13 August 2026
Compass began tracking this trial’s registry record on the date of its first update above. Changes before then are not listed.
Relevant to you?